25 results
Beta-Blockers in Cirrhosis
 • Pathophysiology
 • Indications:  Prevention of decompensation, Prevention of first variceal bleeding,
in Cirrhosis • Pathophysiology ... gastropathy • Dosing ... BetaBlockers #Cirrhosis #hepatology ... #management #pharmacology ... #indications #dosing
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
algorithm for the treatment ... of cancer-associated ... for appropriate dosing ... Anticoagulation #Management ... #Hematology #Oncology
Treatment algorithm for VTE in Malignancy

(A) Suggested treatment algorithm for symptomatic and incidental DVT or PE
incidental DVT or PE in cancer ... thrombosis in cancer ... bleeding risk during ... Anticoagulation #Management ... #Hematology #Oncology
Managing warfarin INR

Warfarin dosage must be individualized according to the patient's response to the drug, and
#management #algorithm ... #pharmacology # ... treatment #medications ... decisionaid #cardiology #hematology ... #warfarin #dosing
Systemic Therapy for Hepatocellular Carcinoma - AGA Clinical Practice Guideline

First Line Treatment for HCC with Preserved
First Line Treatment ... Preserved Liver Function ... #Management #Hepatology ... Gastroenterology #oncology ... #Pharmacology
Adult-Onset Still's Disease
Clinical triad: Fever, Arthralgia/arthritis, Skin rash ± odynophagia
+ Biological inflammation: Increased neutrophils, Hyperferritinemia, decreased
decreased glycosylated fraction ... hemopathies, solid cancers ... Disease #diagnosis #management ... #treatment #rheumatology
Atopic Dermatitis - Topical Treatment Options 
First Line: Topical Corticosteroids 
  - High Potency: Betamethasone
Dermatitis - Topical Treatment ... therapy is non-pharmacologic ... If patients using ... Dermatitis #Topical #Treatment ... #Dermatology #Management
DPP4 Inhibitors - Normal and Renal Dosing

Increase Incretins (GLP-I & GIP) -> Stimulates Insulin, Inhibits Glucagon
Normal and Renal Dosing ... has very minimal chance ... check the kidney function ... #Pharmacology # ... Management #Diabetes
(DOAC interactions) Cancer-treatment specific inducers (↑) and inhibitors (↓)
of cytochrome p450 CYP3A4 and P-glycoprotein.

DOACs are substrates
interactions) Cancer-treatment ... #Chemotherapy #Oncology ... #Hematology #Interactions ... #Table #Pharmacology
Differentiation Syndrome in APML
Epidemiology:
 • Incidence: common in APL (2-48% depending on the study)
 • Triggers:
Triggers: ATRA treatment ... Pathophysiology ... Renal Failure Treatment ... APML #diagnosis #management ... #hematology #oncology